

## **The Election Committee's proposal to the Annual General Meeting 2022 in Active Biotech AB (publ) along with information on the proposed Board members and reasoned statement**

---

### ***The Election Committee's proposal***

The Election Committee, comprising Michael Shalmi (Chairman of the Board), Mats Arnhög (MGA Holding), Per Colleen (Fourth Swedish National Pension Fund) and Peter Thelin, proposes the following:

*Chairman of the Meeting:* attorney-at-law Erik Sjöman or, if he has an impediment to attend, the person instead appointed by the Board of Directors.

*Number of members and alternate members of the Board of Directors:* six ordinary members with no alternates.

*Fees payable to the Board of Directors:* unchanged SEK 500,000 to the Chairman of the Board and SEK 200,000 to each of the other Board members who are not employed by the Company. A member of the Board who performs work for the Company outside the scope of the Board work may also receive remuneration on market terms for such work performed.

*Board of Directors:* re-election of Michael Shalmi, Uli Hacksell, Peter Thelin, Axel Glasmacher, Aleksandar Danilovski and Elaine Sullivan.

*Chairman of the Board:* re-election of Michael Shalmi.

*Number of auditors and alternate auditors:* one auditor with no alternates.

*Fees payable to the auditor:* in accordance with approved invoices within the scope of the tender.

*Auditors:* re-election of KPMG AB. The proposal regarding auditor is in accordance with the recommendation by the Board of Directors.

*Election Committee:* The Election Committee proposes that the Meeting assign the Chairman of the Board the task of convening an Election Committee, based on the ownership structure at the end of September 2022, comprising the Chairman of the Board and one member appointed by each of the three largest shareholders of the Company. The Election Committee shall remain in place until the following Election Committee has been appointed. If a member of the Election Committee no longer represents one of the three largest shareholders in the Company, the Election Committee is entitled to dismiss the member. In the event that a member of the Election Committee resigns or is dismissed, the Election Committee may appoint another member nominated by the major shareholders to replace such a member. The Election Committee shall perform its duties in accordance with the stipulations for Election Committees stated in the Swedish Code of Corporate Governance.

### ***Information on the proposed re-elected Board members***

#### **Michael Shalmi**

Chairman since 2019.

*Born:* 1965.

*Education:* Physician from University of Copenhagen and MBA from Scandinavian International Management Institute in Copenhagen

*Shareholding in the Company:* 336,718 shares. Moreover, Michael Shalmi holds 1,500,000 call options issued by MGA Holding and Nordstjernan on market terms.

*Other assignments:* CEO and owner of Aligned Clinical Management Services. CEO at P/S Momentum Energy Jutlandia, K/S Momentum Energy Jutlandia Development and K/S Momentum Energy Hanstholm. Chairman of the Board of Momentum Gruppen A/S and Curexsys AG.

*Previous assignments:* Managing Director and Head of Principal Investments of Novo Holdings A/S. Board member of Evotec AG

### **Uli Hacksell**

Board member since 2019.

*Born:* 1950.

*Education:* Master of Pharmacy, PhD in Medicinal Chemistry, Professor in Organic Chemistry.

*Shareholding in the Company:* 21,000 shares.

*Other assignments:* Chairman of Medivir AB and Annexin Pharmaceuticals AB. Uli Hacksell is board member of Index Pharmaceuticals Holding AB and Synact Pharma AB.

*Previous assignments:* Chief Executive Officer of ACADIA Pharmaceuticals and Chief Executive Officer and Chairman of the Board of Cerecor.

### **Peter Thelin**

Board member since 2011.

*Born:* 1956.

*Education:* Graduate of Stockholm School of Economics.

*Shareholding in the Company:* 4,715,220 shares (privately and through company).

*Other assignments:* Board member and Partner of Brummer & Partners AB. Board member of B & P Fund Services AB, Brummer Investor Relations AB, Brummer Multi-Strategy AB, Carve Intressenter AB, East Bay AB, ELC Fastigheter AB, Mats Sundin Fellowship, Sjuenda Holding AB, Sjuenda Persbo Holding AB, Sjuenda Jordbruk AB, Sjuenda Gård AB, Rebellion Oil AB, Stiftelsen S:ta Ragnhilds friskolor i Södertälje and S:ta Ragnhild gymnasiet AB. Chairman in Stiftelsen Hjärnfonden. Deputy board member of French River 1 AB and French River 2 AB.

*Previous assignments:* CEO of Carve Capital AB. Chairman of the Board of Jemtia AB, SRE Högfors AB and Acrux Entreprenad AB. Board member of CPB Energy AB, Valot Invest Sweden AB, Henvålens Fjällgård AB, Järna Mejeri AB and Psoriasis + Creams Sweden AB.

### **Axel Glasmacher**

*Born:* 1960.

*Education:* Doctor of Medicine, since 2009 an adjunct professor of medicine at the University of Bonn, Germany.

*Shareholding in the Company:* 40,000 shares.

*Other assignments:* Member of the Clinical Advisory Board of Oncopeptides AB and member of the Board of Cancer Drug Development Forum. In addition, Axel Glasmacher is the Non-Executive Chairperson of the Board of Directors to 4D pharma plc and a member of the Supervisory Board of Selvita S.A. (Ryvü S.A.) and the board of AvenCell Therapeutics Inc.

*Previous assignments:* Head of Global Clinical R&D and Senior Vice President for Celgene.

### **Aleksandar Danilovski**

*Born:* 1974.

*Education:* Ph.D. in Chemistry from Cambridge University and University of Zagreb.

*Shareholding in the Company:* 106,688 shares.

*Other assignments:* Chief Scientific Officer (CSO) at Xellia Pharmaceuticals, a specialty pharmaceutical company headquartered in Denmark. Board member of Pharmaero ApS and Member of the Scientific Selection Board of Novo Holdings – REPAIR Impact Fund.

*Previous assignments:* Head of European R&D for Barr Laboratories, Inc. and board member in PLIVA Pharmaceuticals.

### **Elaine Sullivan**

*Born:* 1961.

*Education:* Ph.D. in Molecular Virology from the University of Edinburgh.

*Shareholding in the Company:* None.

*Other assignments:* CEO of Keltic Pharma Therapeutics. She is a Non-Executive Director of the IP Group plc and a Member of the Supervisory Board of Evotec AG.

*Previous assignments:* CEO of Curadh Therapeutics which she co-founded in 2020. She was a member of the most senior R&D management teams in Lilly and AstraZeneca. At Lilly she worked as Vice President Global External Research & Development and she held various positions at AstraZeneca including, Vice President R&D; Head of New Opportunities Therapy Area and Vice President, Science & Technology. She was the Co-founder of Carrick Therapeutics where she served as Chief Executive Officer.

Information about the proposed Board members independence in relation to the Company, the executive management and major shareholders in the Company is set out below.

***The Election Committee's reasoned statement in relation to its proposal for Board of Directors, etc.***

The Election Committee has held one formal meeting regarding their work prior to the Annual General Meeting 2022. In addition thereto, the members have been in continuous e-mail-and telephone contact. The Election Committee has, as basis for its work, been provided with an evaluation of the Board and its work, performed by the Chairman of the Board. In the evaluation, the members of the Board have provided their views on working methods, Board material, their own and other members' work efforts as well as the scope of the mandate. Based on this information, the Election Committee has assessed what competence and experience a position on the Board requires.

In light of, among other things, the evaluation described above, the Election Committee has received a very positive impression of the Board's work in 2021. It is the Election Committee's opinion that the Board proposed to be appointed at the Annual General Meeting 2022 will have a composition well suited to the Company's operations, stage of development and other factors, and that the Board members are characterized by diversity in their expertise, experience and background.

In relation to the composition of the Board, the provisions of rule 4.1 of the Swedish Corporate Governance Code have been applied as diversity policy and with regard to the objectives of that policy. This has resulted in the Election Committee's proposal on members of the Board to the Annual General Meeting. The gender distribution within the Board is uneven. The Election Committee strives to change this.

None of the proposed members of the Board are members of the executive management, or the management of any subsidiary. It is the Election Committee's assessment that all proposed members are independent vis-à-vis the Company and the executive management. It is further the Election Committee's assessment that all of the proposed members of the Board are independent vis-à-vis the Company's major shareholders.

April 2022

**The Election Committee of Active Biotech AB (publ)**